Pseudo-mannosylated compounds inhibit DC-SIGN mediated HIV infection by competitive inhibition and by interfering with DC-SIGN signal
-
1
Università degli Studi di Milano, Department of Biomedical and Clinical Sciences "L.Sacco", Italy
-
2
Università degli studi di Milano, Department of Organic and Industrial Chemistry, Italy
-
3
Università degli Studi di Milano, Department of Medical and Transplantation Physiopathology, Italy
Background: DC-SIGN is involved in the initial stages of infection by HIV. DC-SIGN, by binding high mannose glycan on HIV gp120, mediates trans infection of CD4 T cells. HIV interaction with DC-SIGN promote immunosuppressive responses that interfere with TLRs signalling, so favouring the persistence of the virus. We synthesized pseudo-mannosylated compounds in the attempt to compete with binding of DC-SIGN to HIV gp120 and interfere with the immunosuppressive DC-SIGN signalling.
Methods: The ability of the compounds to block HIV-1 infection and their toxicity were assessed in cellular and human cervical explant models. Laboratory strain and primary isolates both R5 tropic and X4 tropic were tested. Gene expression profile after treatment of MDDCs with the compounds was evaluated.
Results: Two of the compounds abrogated almost completely the transmission of different HIV strains to CD4 T cells and the infection of cervical explants. This activity was associated with a significant increase in the production of the antiviral cytokine IFNβ and of β chemokines. The production of inflammatory cytokines (IL-6, IL-1 β, TNFα and IFNγ) was increased, whereas IL-10, CCR5 and CXCR4 expression was not modified. The toxicity of the compounds was neglectable.
Conclusion: Pseudo-manosylated compounds competitively inhibit HIV binding to DC-SIGN, blocking infection in trans. Furthermore, by interacting with DC-SIGN, the compounds induce immune activation and proinflammatory responses. The production of β chemokines CCL3, CCL4 and RANTES, that compete with the virus binding to CCR5 co-receptor, contributes to antiviral activity. These features make such compounds good candidates to develop new topical microbicides.
Keywords:
HIV,
DC-SIGN,
Glycomimetic compounds,
Dendritic Cells,
Toll-Like Receptors
Conference:
15th International Congress of Immunology (ICI), Milan, Italy, 22 Aug - 27 Aug, 2013.
Presentation Type:
Abstract
Topic:
Immune receptors and signaling
Citation:
Berzi
A,
Varga
N,
Antonazzo
P,
Cetin
I,
Biasin
M,
Trabattoni
D,
Bernardi
A and
Clerici
M
(2013). Pseudo-mannosylated compounds inhibit DC-SIGN mediated HIV infection by competitive inhibition and by interfering with DC-SIGN signal
.
Front. Immunol.
Conference Abstract:
15th International Congress of Immunology (ICI).
doi: 10.3389/conf.fimmu.2013.02.00168
Copyright:
The abstracts in this collection have not been subject to any Frontiers peer review or checks, and are not endorsed by Frontiers.
They are made available through the Frontiers publishing platform as a service to conference organizers and presenters.
The copyright in the individual abstracts is owned by the author of each abstract or his/her employer unless otherwise stated.
Each abstract, as well as the collection of abstracts, are published under a Creative Commons CC-BY 4.0 (attribution) licence (https://creativecommons.org/licenses/by/4.0/) and may thus be reproduced, translated, adapted and be the subject of derivative works provided the authors and Frontiers are attributed.
For Frontiers’ terms and conditions please see https://www.frontiersin.org/legal/terms-and-conditions.
Received:
11 Mar 2013;
Published Online:
22 Aug 2013.
*
Correspondence:
Dr. Angela Berzi, Università degli Studi di Milano, Department of Biomedical and Clinical Sciences "L.Sacco", Milan, 20157, Italy, angela.berzi@unimi.it